BACKGROUND: The duration of humoral and T and cell response after the infection of SARS-CoV-2 remains unclear. METHODS: We performed a cross-sectional study to assess the virus-specific antibody and memory T and B cell responses in COVID-19 patients up to 343 days after infection. Neutralizing antibodies and antibodies against the receptor-binding domain, spike, and nucleoprotein of SARS-CoV-2 were measured. Virus-specific memory T and B cell responses were analyzed. RESULTS: We enrolled 59 COVID-19 patients, including 38 moderate, 16 mild, and five asymptomatic patients; 31 (52.5%) were men, and 28 (47.5%) were women. The median age was 41 (interquartile range [IQR]: 30-55). The median day from symptom onset to enrollment was 317 days (range 257 to 343 days). We found that approximately 90% of patients still have detectable IgG antibodies against spike and nucleocapsid proteins and neutralizing antibodies against pseudovirus, whereas ~60% of patients had detectable IgG antibodies against receptor binding domain and surrogate virus-neutralizing antibodies. SARS-CoV-2-specific IgG + memory B cell and IFN-γ secreting T cell responses were detectable in over 70% of patients. CONCLUSIONS: SARS-CoV-2-specific immune memory response persists in most patients nearly one year after infection, which provides a promising sign for prevention from reinfection and vaccination strategy.
BACKGROUND: The duration of humoral and T and cell response after the infection of SARS-CoV-2 remains unclear. METHODS: We performed a cross-sectional study to assess the virus-specific antibody and memory T and B cell responses in COVID-19patients up to 343 days after infection. Neutralizing antibodies and antibodies against the receptor-binding domain, spike, and nucleoprotein of SARS-CoV-2 were measured. Virus-specific memory T and B cell responses were analyzed. RESULTS: We enrolled 59 COVID-19patients, including 38 moderate, 16 mild, and five asymptomatic patients; 31 (52.5%) were men, and 28 (47.5%) were women. The median age was 41 (interquartile range [IQR]: 30-55). The median day from symptom onset to enrollment was 317 days (range 257 to 343 days). We found that approximately 90% of patients still have detectable IgG antibodies against spike and nucleocapsid proteins and neutralizing antibodies against pseudovirus, whereas ~60% of patients had detectable IgG antibodies against receptor binding domain and surrogate virus-neutralizing antibodies. SARS-CoV-2-specific IgG + memory B cell and IFN-γ secreting T cell responses were detectable in over 70% of patients. CONCLUSIONS:SARS-CoV-2-specific immune memory response persists in most patients nearly one year after infection, which provides a promising sign for prevention from reinfection and vaccination strategy.
Authors: Gregory Milne; Thomas Hames; Chris Scotton; Nick Gent; Alexander Johnsen; Roy M Anderson; Tom Ward Journal: Lancet Respir Med Date: 2021-10-21 Impact factor: 30.700
Authors: Michael J Peluso; Amelia N Deitchman; Leonel Torres; Nikita S Iyer; Sadie E Munter; Christopher C Nixon; Joanna Donatelli; Cassandra Thanh; Saki Takahashi; Jill Hakim; Keirstinne Turcios; Owen Janson; Rebecca Hoh; Viva Tai; Yanel Hernandez; Emily A Fehrman; Matthew A Spinelli; Monica Gandhi; Lan Trinh; Terri Wrin; Christos J Petropoulos; Francesca T Aweeka; Isabel Rodriguez-Barraquer; J Daniel Kelly; Jeffrey N Martin; Steven G Deeks; Bryan Greenhouse; Rachel L Rutishauser; Timothy J Henrich Journal: Cell Rep Date: 2021-08-06 Impact factor: 9.995